Mortality Outcomes
death, cancer of any type, stroke, ESRD, Deaths, deaths
CVD, STROKE, SECONDARY, END-STAGE RENAL DISEASE, ESRD
Canadian participants (n = 553) were excluded from long-term follow-up because a lack of identifying information precluded the acquisition of comprehensive mortality records for the posttrial period, leaving 32 804 in the current study’s analytic sample (15 002, 8898, and 8904 in the chlorthalidone, amlodipine, and lisinopril groups, respectively). Deaths that occurred during the in-trial period were ascertained and classified by investigators and confirmed by medical records, including death certificates. If the cause of death was unknown to an investigator, a death certificate was obtained from the NDI. Posttrial mortality data, including date and cause of death, were obtained from the NDI Plus service, as was information for unknown causes of in-trial deaths. Details of the categorization of the causes of death and the handling of The primary end point of this long-term follow-up study was mortality due to CVD, which was defined as death due to MI, stroke, or HF. Key secondary outcomes included all-cause mortality, mortality due to CHD, stroke mortality, HF mortality, and mortality due to end-stage renal disease (ESRD). Additional mortality outcomes included death due to the following causes: other CVD falling outside the predefined category, cancer of any type, and other non-CVD causes.